...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Medical Physics/Association of Medical Physicists of India >Establishment of a New Three-Dimensional Dose Evaluation Method Considering Variable Relative Biological Effectiveness and Dose Fractionation in Proton Therapy Combined with High-Dose-Rate Brachytherapy
【24h】

Establishment of a New Three-Dimensional Dose Evaluation Method Considering Variable Relative Biological Effectiveness and Dose Fractionation in Proton Therapy Combined with High-Dose-Rate Brachytherapy

机译：建立一种新的三维剂量评价方法，其考虑变量相对生物效果和剂量分馏与高剂量速率近距离放射治疗

获取原文
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose: The purpose of this study is to evaluate the influence of variable relative biological effectiveness (RBE) of proton beam and dose fractionation has on dose distribution and to establish a new three-dimensional dose evaluation method for proton therapy combined with high-dose-rate (HDR) brachytherapy. Materials and Methods: To evaluate the influence of variable RBE and dose fractionation on dose distribution in proton beam therapy, the depth-dose distribution of proton therapy was compared with clinical dose, RBE-weighted dose, and equivalent dose in 2 Gy fractions using a linear-quadratic-linear model (EQD2subLQL/sub). The clinical dose was calculated by multiplying the physical dose by RBE of 1.1. The RBE-weighted dose is a biological dose that takes into account RBE variation calculated by microdosimetric kinetic model implemented in Monte Carlo code. The EQD2subLQL/sub is a biological dose that makes the RBE-weighted dose equivalent to 2 Gy using a linear-quadratic-linear (LQL) model. Finally, we evaluated the three-dimensional dose by taking into account RBE variation and LQL model for proton therapy combined with HDR brachytherapy. Results: The RBE-weighted dose increased at the distal of the spread-out Bragg peak (SOBP). With the difference in the dose fractionation taken into account, the EQD2subLQL/sub at the distal of the SOBP increased more than the RBE-weighted dose. In proton therapy combined with HDR brachytherapy, a divergence of 103% or more was observed between the conventional dose estimation method and the dose estimation method we propose. Conclusions: Our dose evaluation method can evaluate the EQD2subLQL/sub considering RBE changes in the dose distribution.
机译：目的：本研究的目的是评估质子梁和剂量分馏的可变相对生物效果（RBE）对剂量分布的影响，并建立一种新的三维剂量评价方法，用于质子疗法与高剂量相结合速率（HDR）近距离放射治疗。材料和方法：为了评价变量RBE和剂量分馏对质子束治疗中剂量分布的影响，将质子疗法的深度剂量分布与临床剂量，RBE加权剂量和2 GY级分中的等效剂量进行比较线性 - 二次线性模型（EQD2 LQL ）。通过将物理剂量乘以1.1的rbe来计算临床剂量。 RBE加权剂量是一种生物剂量，其考虑了通过在蒙特卡罗代码中实施的微量微量动力学模型计算的RBE变化。 EQD2 LQL 是一种生物剂量，其使用线性 - 二次线性（LQL）模型使RBE加权剂量相当于2GY。最后，我们通过考虑RBE变异和LQL模型来评估三维剂量，用于质子疗法与HDR近距离放射治疗相结合。结果：RBE加权剂量在扩散布拉格峰（SOBP）的远端增加。随着考虑剂量分馏的差异，SOBP远端的EQD2 <亚> LQL 比RBE加权剂量增加。在质子疗法结合HDR近距离放射治疗中，在常规剂量估计方法和我们提出的剂量估计方法之间观察到103％或更多的分歧。结论：我们的剂量评价方法可以考虑rbe在剂量分布中的变化来评估EQD2 Lql 。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号